Description | CD166 Antibody, anti-human, PE-Vio® 770, REAfinity™. Clone REA442 recognizes the human CD166 antigen, a single-pass type I membrane protein also known as activated leukocyte cell adhesion molecule (ALCAM). CD166, a member of the immunoglobulin superfamily and a ligand for the lymphocyte antigen CD6, mediates homophilic and heterophilic adhesion. It is expressed on activated leukocytes T cells, B cells, monocytes, hematopoietic stem cells (HSCs), metastasizing melanoma, neuronal cells, endothelial cells, hematopoiesis-supporting osteoblastic cell lines, and mesenchymal stem cells (MSCs). CD166 expression is pathologically correlated with aggressive disease in a variety of cancers including melanoma, prostate, breast, ovarian, esophageal, and bladder cancers. It is also a universal functional marker of murine and human HSCs and osteoblasts within the hematopoietic niche and it is involved in modulating HSC-niche interactions and HSC fate. | Additional information: Clone REA442 displays negligible binding to Fc receptors. |
Product Specific References | Chitteti, B. R. et al. (2014) CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 124 (4): 519-529. | Degen, W. G. et al. (1998) MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am. J. Pathol. 152 (3): 805-813. | Ni, C. et al. (2013) Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis. PLoS One 8 (8): e70958. |